An analysis of the NIH-supported sickle cell disease research portfolio

Blood Cells, Molecules, and Diseases

Volumn 54, Issue 2, 2015, Pages 198-205

  Gavini, Nara ^a   Hoots, W Keith ^a   Mensah, George A ^a   Hanspal, Manjit ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Grant mechanisms; National heart, lung, and blood institute (U.S.); Research projects grants; Sickle cell disease

Indexed keywords

HEMOGLOBIN BETA CHAIN; GLOBIN;

ADHESION; AMINO ACID SUBSTITUTION; ANALGESIA; ANEMIA; ARTICLE; CAREER; CHRONIC PAIN; CLINICAL RESEARCH; DATA ANALYSIS; ERYTHROCYTE; FUNDING; GENE EXPRESSION; GLOBIN GENE; HUMAN; INFECTION; MEDICAL RESEARCH; NATIONAL HEALTH ORGANIZATION; NEUROLOGICAL COMPLICATION; ORGAN INJURY; PATIENT CARE; SICKLE CELL ANEMIA; TRANSLATIONAL RESEARCH; VASCULAR DISEASE; ANEMIA, SICKLE CELL; BLOOD VESSEL; CELL ADHESION; ECONOMICS; FINANCIAL MANAGEMENT; GENETICS; METABOLISM; NERVOUS SYSTEM; ORGANIZATION AND MANAGEMENT; PAIN; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; TECHNOLOGY; UNITED STATES;

ANEMIA, SICKLE CELL; BIOMEDICAL RESEARCH; BLOOD VESSELS; CELL ADHESION; ERYTHROCYTES; FINANCING, ORGANIZED; GENE EXPRESSION; GLOBINS; HUMANS; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (U.S.); NERVOUS SYSTEM; PAIN; PAIN MANAGEMENT; TECHNOLOGY TRANSFER; UNITED STATES;

EID: 84922580417     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2014.11.001     Document Type: Article

References (27)

1. Strasser B.J. Perspectives: molecular medicine "Sickle cell anemia, a molecular disease". Science 1999, 286:1488-1490.
2. Ingram V.M. Sickle-cell anemia hemoglobin: the molecular biology of the first "molecular disease"-the crucial importance of serendipity. Genetics 2004, 167:1-7.
3. Steinberg M.H. Sickle cell anemia, the first molecular disease: overview of molecular etiology, pathophysiology, and therapeutic approaches. ScientificWorldJournal 2008, 8:1295-1324.
4. Desai P.C., Ataga K.I. The acute chest syndrome of sickle cell disease. Expert. Opin. Pharmacother. 2013, 14:991-999.
5. Hollins M., Stonerock G.L., Kisaalita N.R., Jones S., Orringer E., Gil K.M. Detecting the emergence of chronic pain in sickle cell disease. J. Pain Symptom Manag. 2012, 43:1082-1093.
6. Ali N., Srey R., Pavlakis S. Hemoglobinopathies and stroke: strategies for prevention and treatment. Curr. Treat. Options Cardiovasc. Med. 2012, 14:227-236.
7. Minniti C.P., Eckman J., Sebastiani P., Steinberg M.H., Ballas S.K. Leg ulcers in sickle cell disease. Am. J. Hematol. 2010, 85:831-833.
8. Zhang Y., Dai Y., Wen J., Zhang W., Grenz A., Sun H., Tao L., Lu G., Alexander D.C., Milburn M.V., Carter-Dawson L., Lewis D.E., Zhang W., Eltzschig H.K., Kellems R.E., Blackburn M.R., Juneja H.S., Xia Y. Detrimental effects of adenosine signaling in sickle cell disease. Nat. Med. 2011, 17:79-86.
9. Hassell K.L. Population estimates of sickle cell disease in the U.S. Am. J. Prev. Med. 2010, 38:S512-S521.
10. Panepinto J.A., Bonner M. Health-related quality of life in sickle cell disease: past, present, and future. Pediatr. Blood Cancer 2012, 59:377-385.
11. Robb E.L., Page M.M., Stuart J.A. Mitochondria, cellular stress resistance, somatic cell depletion and lifespan. Curr. Aging Sci. 2009, 2:12-27.
12. Bartolucci P., Galactéros F. Clinical management of adult sickle-cell disease. Curr. Opin. Hematol. 2012, 19:149-155.
13. Edwards L.Y., Edwards C.L. Psychosocial treatments in pain management of sickle cell disease. J. Natl. Med. Assoc. 2010, 102:1084-1094.
14. Candrilli S.D., O'Brien S.H., Ware R.E., Nahata M.C., Seiber E.E., Balkrishnan R. Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease. Am. J. Hematol. 2011, 86:273-277.
15. Green N.S., Barral S. Genetic modifiers of HbF and response to hydroxyurea in sickle cell disease. Pediatr. Blood Cancer 2011, 56:177-181.
16. Smith-Whitley K., Thompson A.A. Indications and complications of transfusions in sickle cell disease. Pediatr. Blood Cancer 2012, 59:358-364.
17. Asbeutah A., Gupta R., Al-Saeid O., Ashebu S., Al-Sharida S., Mullah-Ali A., Mustafa N.Y., Adekile A. Transcranial Doppler and brain MRI in children with sickle cell disease and high hemoglobin F levels. Pediatr. Blood Cancer 2014, 61:25-38.
18. Kwiatkowski J.L., Yim E., Miller S., Adams R.J., STOP 2 Study Investigators Effect of transfusion therapy on transcranial Doppler ultrasonography velocities in children with sickle cell disease. Pediatr. Blood Cancer 2011, 56:777-782.
19. Kharbanda S., Smith A.R., Hutchinson S.K., McKenna D.H., Ball J.B., Lamb L.S., Agarwal R., Weinberg K.I., Wagner J.E. Unrelated donor allogeneic hematopoietic stem cell transplantation for patients with hemoglobinopathies using a reduced-intensity conditioning regimen and third-party mesenchymal stromal cells. Biol. Blood Marrow Transplant. 2014, 20:581-586.
20. Thompson L.M., Ceja M.E., Yang S.P. Stem cell transplantation for treatment of sickle cell disease: bone marrow versus cord blood transplants. Am. J. Health Syst. Pharm. 2012, 69:1295-1302.
21. Dong A., Rivella S., Breda L. Gene therapy for hemoglobinopathies: progress and challenges. Transl. Res. 2013, 161:293-306.
22. Zou J., Mali P., Huang X., Dowey S.N., Cheng L. Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. Blood 2011, 118:4599-4608.
23. Hoots W.K., Shurin S.B. Future directions of sickle cell disease research: the NIH perspective. Pediatr. Blood Cancer 2012, 59:353-357.
24. Manwani D., Frenette P.S. Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies. Blood 2013, 122:3892-3898.
25. Mack A.K., Kato G.J. Sickle cell disease and nitric oxide: a paradigm shift?. Int. J. Biochem. Cell Biol. 2006, 38:1237-1243.
26. Suzuki M., Yamamoto M., Engel J.D. Fetal globin gene repressors as drug targets for molecular therapies to treat the β-globinopathies. Mol. Cell. Biol. 2014, 34:3560-3569.
27. Uda M., Galanello R., Sanna S., Lettre G., Sankaran V.G., Chen W., Usala G., Busonero F., Maschio A., Albai G., Piras M.G., Sestu N., Lai S., Dei M., Mulas A., Crisponi L., Naitza S., Asunis I., Deiana M., Nagaraja R., Perseu L., Satta S., Cipollina M.D., Sollaino C., Moi P., Hirschhorn J.N., Orkin S.H., Abecasis G.R., Schlessinger D., Cao A. Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:1620-1625.